CBA Bioentrepreneur Club Event07/22/2009 - 07/22/2009

CBA Bioentrepreneur Club Event
Personalized Medicine : Its Promises and Challenges
7/22 (Wed) 6:30-8:30pm
at Fenwick & West LLP
801 California Street
Mountain View, CA 94041
 
Costs: Free for members, $20 Annual Membership, $100 Lifetime Membership
 
Our panelists feature
Dr. Gary Zweiger, VP of Business Development for BioNanomatrix, Inc.
Dr. Michelle Chen,  Public Health Product Manager at Life Technologies
 
Panel discussion will explore
(a) Discovery of biomarkers
(b) Validation of biomarkers
(c) Clinical utility of biomarkers
(d) Design of IVD diagnostic tests & regulatory pathways etc.
(e) Value creation model
 
Biographies:
Dr. Gary Zweiger has worked in Genomics since the inception of the field in the mid-90's, first consulting for investment banks and venture capital firms and then working for and providing leadership in business and market development, strategic planning,  and new business creation at Incyte Genomics, Agilent Technologies, Applied Biosystems, and Affymetrix.  He is also author of a popular book on the race to sequencing the human genome (Transducing the Genome; McGraw-Hill, 2001).   Gary received his doctoral degree from Stanford University Medical School’s Dept of Genetics and completed his post-doctoral fellowship at Genentech Inc. 
 
BioNanomatrix is developing unique nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome.  The company’s patented technology delivers comprehensive analyses of genomic and epigenomic information with single-molecule sensitivity, while avoiding the fragmentation and complex data reassembly required by other approaches.
 
Michelle Chen is currently managing products of public health and environmental Dx solutions at Applied Biosystems covering many areas including the novel H1N1 flu, avian flu and food safety testing.  Her previous position was a Global Marketing Manager and she helped to launch and commercialize numerous new products.  Prior to AB, she was a business/market development manager at Agilent Technologies in the areas of molecular diagnostics and life sciences.  Before Agilent, she was a R&D manager working in the biopharmaceutical industry on cancer and cardiovascular diseases.
 

Michelle has a Ph.D. in Biochemistry from University of Washington and did her post-doctoral at UCSF. She also has a Bioinformatics certificate from Stanford University.


Back